Sanara MedTech Inc. SMTI

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived Nasdaq

are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and

reduce healthcare expenditures in the surgical market. Our products are designed to achieve our goal of providing better clinical outcomes

at a lower overall cost for healthcare systems. We strive to be one of the most innovative and comprehensive providers of effective surgical

solutions and are continually seeking to expand our offerings for patients requiring surgical treatments in the United States.

Last close 32.80 2026-10-23
Market cap $301.4M 2026-06-30 share count
52-week range 16.05 - 35.52

Valuation FY2025 figures against the last close

P/S2.9x
P/E—
P/FCF139.5x
EV/EBITDA29.4x
Dividend yield—
Diluted EPS-4.36

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $103.1M$86.7M$65.0M$45.8M$24.1M$15.6M$11.8M$5.8M$6.3M$5.5M
Cost of revenue $7.5M$8.1M$7.9M$6.4M$2.3M$1.6M$1.2M$507.4K$806.0K$943.6K
Gross profit $95.6M$78.5M$57.1M$39.5M$21.8M$14.0M$10.6M$5.3M$5.5M$4.6M
R&D $5.1M$2.8M$4.1M$3.4M$558.7K$40.2K————
SG&A $78.7M$71.7M$57.0M$46.0M$28.1M$18.7M$13.1M$5.7M$5.3M$3.9M
Total operating expenses $88.3M$77.3M$61.4M$52.0M$29.2M$19.0M$13.3M$5.8M$5.4M$4.8M
Operating income $7.3M$1.3M-$4.2M-$12.5M-$7.4M-$5.0M-$2.7M-$501.9K$120.4K-$272.1K
Interest expense $6.8M$3.1M$475.8K$284.7K$711$11.5K$105.9K$86.6K$126.8K$174.5K
Pre-tax income -$393.1K-$1.9M-$4.4M-$13.9M-$8.0M-$4.4M-$2.8M-$600.6K$331.3K-$415.7K
Income tax —$48.4K—$5.8M—$0$0$0$0$0
Net income $37.6M$9.7M$4.3M-$7.9M-$7.9M-$4.4M-$2.8M-$600.6K$331.3K-$415.7K
EPS, basic -4.36-1.14-0.52-1.00-1.08-0.76-1.320.000.00-0.01
EPS, diluted -4.36-1.14-0.52-1.00-1.08-0.76-1.320.000.00-0.01
Shares, diluted (wtd. avg.) 8.6M8.5M8.3M7.9M7.3M5.7M2.1M217.2M208.6M108.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $16.6M$15.9M$5.1M$9.0M$18.7M$455.4K$6.6M$176.4K$463.2K$833.5K
Receivables ———$6.8M$2.9M—————
Inventory $3.9M$2.8M$4.7M$3.5M$2.0M$1.1M$746.5K$465.3K$711.4K$348.5K
Total current assets $33.5M$33.3M$19.0M$20.6M$24.6M$4.5M$8.9M$1.7M$2.0M$2.0M
Property, plant and equipment $457.0K$432.3K$1.3M$1.4M$1.6M$678.6K$205.0K$18.8K$63.2K$34.9K
Goodwill $3.6M$3.6M$3.6M$3.6M——————
Other intangibles $18.6M$23.5M$44.9M$31.5M$4.7M$3.1M$1.5M$0$117.3K$140.3K
Total assets $72.9M$88.1M$73.9M$61.0M$36.4M$9.8M$11.1M$1.7M$2.2M$2.2M
Accounts payable ———$1.4M$438.2K$271.3K$337.5K$156.7K$225.5K$238.2K
Short-term debt ——$580.4K———————
Total current liabilities $18.6M$15.3M$13.8M$12.8M$6.0M$3.5M$2.6M$1.1M$2.1M$1.4M
Long-term debt $46.0M$30.7M$9.1M———————
Total liabilities $67.0M$49.2M$29.3M$19.3M$6.2M$4.0M$4.7M$1.1M$2.1M$2.6M
Retained earnings -$75.3M-$37.8M-$28.0M-$23.4M-$15.2M-$7.0M-$2.7M$138.3K-$46.9M-$47.2M
Total equity $5.9M$39.4M$44.6M$41.7M$30.2M$5.8M$6.4M$586.8K$102.5K-$423.1K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $6.8M-$23.8K-$3.2M-$5.6M-$4.8M-$4.0M-$2.2M$277.1K-$139.9K$409.2K
Depreciation and amortisation $3.9M$4.9M$456.1K$407.8K$220.6K$67.8K$120.0K———
Stock-based compensation $5.2M$4.4M$3.4M$2.7M$2.7M$1.4M$0———
Capital expenditure $4.6M$205.8K$265.2K$147.0K$171.9K$544.4K$182.8K$8.5K$43.9K$3.0K
Investing cash flow -$15.0M-$6.6M-$10.2M-$3.5M-$5.3M-$2.7M-$1.2M-$8.5K-$85.9K-$3.0K
Financing cash flow $8.9M$17.4M$9.6M-$627.3K$28.3M$622.3K$9.8M$0-$144.6K$244.9K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-017156.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M Revenue, FY2016: 5.5M Gross profit, FY2016: 4.6M Net income, FY2016: -415.7K Revenue, FY2017: 6.3M Gross profit, FY2017: 5.5M Net income, FY2017: 331.3K Revenue, FY2018: 5.8M Gross profit, FY2018: 5.3M Net income, FY2018: -600.6K Revenue, FY2019: 11.8M Gross profit, FY2019: 10.6M Net income, FY2019: -2.8M Revenue, FY2020: 15.6M Gross profit, FY2020: 14M Net income, FY2020: -4.4M Revenue, FY2021: 24.1M Gross profit, FY2021: 21.8M Net income, FY2021: -7.9M Revenue, FY2022: 45.8M Gross profit, FY2022: 39.5M Net income, FY2022: -7.9M Revenue, FY2023: 65M Gross profit, FY2023: 57.1M Net income, FY2023: 4.3M Revenue, FY2024: 86.7M Gross profit, FY2024: 78.5M Net income, FY2024: 9.7M Revenue, FY2025: 103.1M Gross profit, FY2025: 95.6M Net income, FY2025: 37.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $5.5M $6.3M $5.8M $11.8M $15.6M $24.1M $45.8M $65.0M $86.7M $103.1M
Gross profit $4.6M $5.5M $5.3M $10.6M $14.0M $21.8M $39.5M $57.1M $78.5M $95.6M
Net income -$415.7K $331.3K -$600.6K -$2.8M -$4.4M -$7.9M -$7.9M $4.3M $9.7M $37.6M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
STE STERIS plc $22.63B 29.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.80B 27.8x 7.2%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%